Axim Biotechnologies, Inc (AXIM) financial statements (2021 and earlier)

Company profile

Business Address 45 ROCKEFELLER PLAZA
NEW YORK, NY 10022
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 1,8062,058713134661
Cash and cash equivalents 1,8062,058713134661
Receivables 55   
Inventory, net of allowances, customer advances and progress billings 10938201 
Inventory 10938201 
Prepaid expense   4177872
Intangible current assets   6363 
Other undisclosed current assets 2024151875
Total current assets: 2,0232,1131,3741,183738
Noncurrent Assets
Property, plant and equipment   1216 
Prepaid expense 77   
Other undisclosed noncurrent assets 54636363 
Total noncurrent assets: 61717579 
Other undisclosed assets 69   
TOTAL ASSETS: 2,0892,1921,4491,262738
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 218442   
Other undisclosed accounts payable and accrued liabilities 218442   
Debt 1,4335,635758501,050
Due to related parties 1,6501,6061,6191,08666
Other liabilities 2323   
Other undisclosed current liabilities   6401,421203
Total current liabilities: 3,3247,7053,0172,5571,319
Noncurrent Liabilities
Long-term debt and lease obligation   46400 
Long-term debt, excluding current maturities   46400 
Other undisclosed noncurrent liabilities 4,847772758  
Total noncurrent liabilities: 4,847772804400 
Total liabilities: 8,1718,4773,8212,9571,319
Stockholders' equity
Stockholders' equity attributable to parent, including: (6,164)(6,333)(2,372)(1,695)(581)
Preferred stock    00
Common stock 65543
Common stock, share subscribed but unissued, subscriptions receivable (41)(24)(20)(53) 
Additional paid in capital 22,86415,92415,6739,033108
Accumulated deficit (28,992)(22,238)(18,070)(10,785) 
Other undisclosed stockholders' equity attributable to parent   40105(692)
Other undisclosed stockholders' equity 8248   
Total stockholders' equity: (6,082)(6,284)(2,372)(1,695)(581)
TOTAL LIABILITIES AND EQUITY: 2,0892,1921,4491,262738

Income statement (P&L) ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues 196484749 
Cost of revenue (9)(43)(154)(50) 
Cost of goods and services sold   (154)(50) 
Gross profit: 1875(107)(1) 
Operating expenses (5,223)(3,154)(3,652)(10,048)(506)
Operating loss: (5,036)(3,149)(3,759)(10,050)(506)
Nonoperating income (expense) (1,719)(1,019)2,05043 
Investment income, nonoperating (1,123)(704)   
Interest and debt expense (140)(315)1,109(43)(33)
Loss from continuing operations before equity method investments, income taxes: (6,894)(4,483)(600)(10,050)(538)
Other undisclosed income (loss) from continuing operations before income taxes 140315(5,210)(43) 
Loss from continuing operations: (6,755)(4,168)(5,810)(10,093)(538)
Loss from discontinued operations     (45)
Net loss available to common stockholders, diluted: (6,755)(4,168)(5,810)(10,093)(583)

Comprehensive Income ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss: (6,755)(4,168)(5,810)(10,093)(583)
Comprehensive loss, net of tax, attributable to parent: (6,755)(4,168)(5,810)(10,093)(583)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: